gms | German Medical Science

102. Jahrestagung der DOG

Deutsche Ophthalmologische Gesellschaft e. V.

23. bis 26.09.2004, Berlin

Topical brimonidine in the treatment of non-arteritic anterior ischemic optic neuropathy: a double-blind, placebo- controlled randomised multicenter trial

Meeting Abstract

Suche in Medline nach

  • corresponding author B. Wilhelm - Steinbeis Transferzentrum for Biomedizinische Optik und Funktionsprüfung, Tübingen
  • H. Lüdtke - Steinbeis Transferzentrum for Biomedizinische Optik und Funktionsprüfung, Tübingen
  • H. Wilhelm - Universitäts-Augenklinik Tübingen, Abt. Pathophysiologie des Sehens und Neuroophthalmologie
  • Arbeitsgruppe BRAION-Multizenterstudie

Evidenzbasierte Medizin - Anspruch und Wirklichkeit. 102. Jahrestagung der Deutschen Ophthalmologischen Gesellschaft. Berlin, 23.-26.09.2004. Düsseldorf, Köln: German Medical Science; 2004. Doc04dogFR.06.03

Die elektronische Version dieses Artikels ist vollständig und ist verfügbar unter:

Veröffentlicht: 22. September 2004

© 2004 Wilhelm et al.
Dieser Artikel ist ein Open Access-Artikel und steht unter den Creative Commons Lizenzbedingungen ( Er darf vervielfältigt, verbreitet und öffentlich zugänglich gemacht werden, vorausgesetzt dass Autor und Quelle genannt werden.




Neuroprotection may be an option in ischemic optic nerve disease. There have been promising reports about the neuroprotective capacity of topical brimonidine in animal studies. Therefore we tested whether 0.2% brimonidine-tartrate could improve the outcome of patients with non-arteritic anterior ischemic optic neuropathy (NAION). The study was stopped after an interim analysis having not proven its feasibility within practicable time frame.


A three-months, double-blind, placebo-controlled, randomised European multicenter trial according to good clinical practice rules. 36 (22m, 14f) patients older 40 y with first eye involvement were included in the study within the first week after visual loss (VA 0.05 - 1.0) and had to show typical signs of NAION. Visual acuity (VA, primary endpoint), visual field (VF, Humphrey 30-2 and Goldmann, quantified by a modified Esterman grid) and automated swinging flashlight test (SWIFT) were done at baseline, 2 weeks, 4 weeks and 12 weeks after first visit. Primary analysis aimed at intention-to-treat group (ITT, n=29), secondary analysis to the per protocol population (PP, n=25). Tolerability and safety were tested in the safety group (n=36). A two-sample two-sided t-test was used for statistical analysis (alpha level at 0.05).


VA did not show statistically significant difference by treatment. There were non-significant trends for better visual field results in the brimonidine group. Adverse events consisting of local irritation were observed six times in the verum and three times in the placebo group. No serious adverse events occurred.


In contradiction to an open retrospective study published by Fazzone et al. (BJO 2003; 87:1193-4) the results of this trial did not hint at any harmful effect of brimonidine in patients suffering from NAION. The functional outcome could not be improved to a relevant and significant amount, although positive trends by brimonidine were observed for VA and both VF methods.